Aimmune Therapeutics, Inc. IPO Research Information

Aimmune Therapeutics, Inc. IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on Aimmune Therapeutics, Inc., and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
Aimmune Therapeutics, Inc.	AIMT - NASDAQ	$14.00-$16.00	$16.00	$17.50	10 million	8/6/2015
Underwriter(s): BofA Merrill Lynch, Credit Suisse, Piper Jaffray
Co-Manager(s):
Industry: Health Care
Filing(s): Filed 2015-07-06 Terms Added 2015-07-27

Aimmune Therapeutics, Inc. Quote & Chart - Click for current quote - AIMT

About Aimmune Therapeutics, Inc. (adapted from Aimmune Therapeutics, Inc. prospectus):
They are a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies.

This description is adapted from AimmuneTherapeutics-AIMT prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as AimmuneTherapeutics-AIMT "AIMT" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.